Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meina Liang

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Analytical Chemistry|May 28, 2020
Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug ConjugateYue Huang, Christopher J Del Nagro, Kemal Balic, et al.
Analytical Chemistry|October 21, 2022
Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody CombinationRuipeng Mu, Yue Huang, Jerome Bouquet, et al.
Practical Laboratory Medicine|November 22, 2017
Development and analytical performance of a new ARCHITECT automated dipeptidyl peptidase-4 immunoassayPhilip M Hemken, Nicolette M Jeanblanc, Tracey Rae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Cytometry. Part B, Clinical Cytometry|December 26, 2015
Role of receptor occupancy assays by flow cytometry in drug developmentJennifer J Stewart, Cherie L Green, Nicholas Jones, et al.
Cytometry. Part B, Clinical Cytometry|November 14, 2015
Recommendations for the development and validation of flow cytometry-based receptor occupancy assaysCherie L Green, Jennifer J Stewart, Carl-Magnus Högerkorp, et al.
Journal of Molecular Biology|July 5, 2011
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokineticsDonna K Finch, Matthew A Sleeman, Jacques Moisan, et al.
Pediatric Blood & Cancer|January 17, 2020
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemiaNirali N Shah, Deepa Bhojwani, Keith August, et al.
Molecular Cancer Therapeutics|December 18, 2013
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signalingNeil R Michaud, Youzhen Wang, Kristen A McEachern, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2017
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Analytical Chemistry|May 28, 2020
Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug ConjugateYue Huang, Christopher J Del Nagro, Kemal Balic, et al.
Analytical Chemistry|October 21, 2022
Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody CombinationRuipeng Mu, Yue Huang, Jerome Bouquet, et al.
Practical Laboratory Medicine|November 22, 2017
Development and analytical performance of a new ARCHITECT automated dipeptidyl peptidase-4 immunoassayPhilip M Hemken, Nicolette M Jeanblanc, Tracey Rae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Cytometry. Part B, Clinical Cytometry|December 26, 2015
Role of receptor occupancy assays by flow cytometry in drug developmentJennifer J Stewart, Cherie L Green, Nicholas Jones, et al.
Cytometry. Part B, Clinical Cytometry|November 14, 2015
Recommendations for the development and validation of flow cytometry-based receptor occupancy assaysCherie L Green, Jennifer J Stewart, Carl-Magnus Högerkorp, et al.
Journal of Molecular Biology|July 5, 2011
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokineticsDonna K Finch, Matthew A Sleeman, Jacques Moisan, et al.
Pediatric Blood & Cancer|January 17, 2020
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemiaNirali N Shah, Deepa Bhojwani, Keith August, et al.
Molecular Cancer Therapeutics|December 18, 2013
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signalingNeil R Michaud, Youzhen Wang, Kristen A McEachern, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2017
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Pageof 8